Lupin obtains USFDA EIR for unit 3 of the Pithampur facility

Date: 2018-12-12   Author: Pankaj Singh  Category: #news

Lupin obtains USFDA EIR for unit 3 of the Pithampur facility

Lupin Limited, a transnational pharmaceutical company based in Mumbai, has reportedly received an Establishment Inspection Report (EIR) from the U.S. regulator for the unit 3 of the facility in Madhya Pradesh.

As per sources familiar with the knowledge of the matter, the unit 3 of Pithampur facility was inspected from June 12 till June 16, in the year 2017. Lupin also mentioned in a BSE filing that this was a pre-approval inspection of a product known as Albuterol Sulfate Inhalation.

Nilesh Gupta, Managing Director, Lupin Limited, said that receiving the Establishment Inspection Report (EIR) for the Pithampur unit 3 facility is a rather motivating development. He also added that this is indeed a proof of their commitment to maintain the highest standards in compliance and quality across their facilities.

For the record, the U.S. Food and Drug Administration (USFDA) issues an Establishment Inspection Report (EIR) to the facility that is the subject of a USFDA or inspection by an FDA-contracted agency when they decide to close the inspection. Establishment Inspection Report (EIR) is the term given by the U.S. Food and Drug Administration (USFDA) for the whole narration of what the FDA investigator or inspector did throughout the time spent in the establishment (i.e. a facility), from the period of introduction till the delivery of the inspectional observations.

Incidentally, the week before Lupin announced the completion of USFDA inspections at its Mandideep location that plays host to the company's Cephalosporin Solid Oral Dosage Form facility, and Cephalosporin and Cardiovascular Pril API facilities. The inspections took place from November 26 till December 4, 2018.

Ironically, despite receiving the EIR from the FDA, Lupin’s stock was trading at Rs 824.15 on BSE, down 1.88 percent from its previous close.

For the record, the company manufactures dry powder inhalers, dermatological products, and metered dose inhalers.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Data Center Power Management Market Expected to Witness High Growth over the Forecast Period 2021 - 2026

Author: Ashwin Naphade

The ' Data Center Power Management market' study now available with Market Study Report, LLC, delivers a concise outlook of the powerful trends driving market growth. This report also includes valuable information pertaining to market share, marke...


Business Value Dashboard Market Outlook | Development Factors, Latest Opportunities and Forecast 2026

Author: Ashwin Naphade

The ' Business Value Dashboard market' study recently added by Market Study Report, LLC, offers an in-depth analysis of the current market trends influencing this business vertical. The study also includes market valuation, market size, revenue fo...


Global Cloud Based Backup Services Market - Detailed Analysis of Current Industry Figures with Forecasts Growth By 2026

Author: Ashwin Naphade

Market Study Report, LLC, provides a research on the ' Cloud Based Backup Services market' which offers a concise summary pertaining to industry valuation, SWOT Analysis, market size, revenue estimation and geographical outlook of the business ver...